BioSpace News Archive

Caprion-HistoGeneX and Viroclinics-DDL announced today a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19.

SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program Funds clinical development and manufacturing of SAB-185, a therapeutic candidate for COVID-19, as well as increased production capacity for rapid response JPEO-CBRND is also providing additional direct funding for first-in-human clinical studies in continued collaboration with BARDA, which remain on track

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020. “The second quarter was very productive for Phathom as we resumed new patient screening and enrollment in both our PHALCON-EE and PHALCON-HP Phase 3 trials and continued to make substantial prog

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report fin

Jaguar Health, Inc. announced the activation of the investigational new drug (IND) application filed by the Company’s wholly owned subsidiary Napo Pharmaceuticals, Inc. (“Napo”) with the FDA for the use of crofelemer (Mytesi®) for prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to accelerate its European activities.

One of the largest active Phase 3 clinical trials in metastatic pancreatic cancer, completes target enrollment ahead of schedule

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of COVID-19 with resilience, prudence and creativity. Despite a 21% year-over-year reduction in quarterly revenue caused by procedure declines, we have made significant progress in commercializing the Genesis

Mind Medicine Inc., the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

Clinical trials remain on track, with Refractory Status Epilepticus (SE) trial expected to begin enrollment shortly CDKL5 deficiency disorder (CDD) pivotal topline results on track for Q3; Conference call to be scheduled to discuss CDD data release and business update Organization further strengthened with new additions to both the Board of Directors and management team RADNOR, Pa.--( BUSINESS WIRE )-- Marinus Pharmaceuticals